Tag: 200-300

Adib, Mehdi; Karimi-Nami, Rahman; Veisi, Hojat published an article in 2016, the title of the article was Palladium NPs supported on novel imino-pyridine-functionalized MWCNTs: efficient and highly reusable catalysts for the Suzuki-Miyaura and Sonogashira coupling reactions.Quality Control of 5-(4-Bromophenyl)pyrimidine And the article contains the following content:

In this article a new heterogeneous nanocatalyst based on palladium supported on functionalized multi-walled carbon nanotubes (MWCNTs) has been introduced. The synthetic process of the mentioned nanocatalyst, MWCNT-imino-pyridine/Pd, has been described. The characterization of the MWCNT-imino-pyridine/Pd was afforded by SEM, EDX, TEM, FTIR, ICP, and XRD. The surface structure of the materials was confirmed using Fourier transform IR (FTIR) spectroscopy. The catalytic activity of MWCNT-imino-pyridine/Pd was tested in Sonogashira and Suzuki-Miyaura cross-coupling reactions affording various derivatives of both aryl alkynes and biaryls. The catalyst can be readily recovered and recycled at least six times without significant loss of catalytic activity. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Quality Control of 5-(4-Bromophenyl)pyrimidine

The Article related to palladium nanoparticle supported iminopyridine functionalized mwcnt, efficient highly reusable catalyst suzuki sonogashira coupling reaction, sonogashira suzuki crosscoupling reaction production derivative aryl alkyne biaryl and other aspects.Quality Control of 5-(4-Bromophenyl)pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 24, 2005, Kishino, Hiroyuki; Moriya, Minoru; Sakamoto, Toshihiro; Takahashi, Hidekazu; Sakuraba, Shunji; Suzuki, Takao; Kanatani, Akio published a patent.Computed Properties of 85386-20-5 The title of the patent was Preparation of imidazopyridine derivatives as melanin-concentrating hormone receptor antagonists. And the patent contained the following:

Title compounds I [R1, R2 = H, halo, etc., further detail on R1, R2 is given; R3 = H, halo, etc.; R4 = H, alkyl; W = single bond, etc.; Ar = optionally substituted aromatic ring, etc. with R7; R7 = halo, etc.] were prepared For example, Pd-catalyzed hydrogenation of 2-isopropyl-6-nitroimidazo[1,2-a]pyridine hydrobromide followed by HATU-mediated acylation with 4′-fluoro-1,1′-biphenyl-4-carboxylic acid afforded compound II. In MCH (Melanin Concentrating Hormone) binding inhibition assays, the IC50 value of compound II was 3.1 nM. Compounds I are claimed useful for the treatment of obesity, diabetes, etc. The experimental process involved the reaction of 5-Phenylpyrimidine-2-carboxylic acid(cas: 85386-20-5).Computed Properties of 85386-20-5

The Article related to imidazopyridine preparation melanin concentrating hormone mch receptor antagonist, antiobesity agent imidazopyridine preparation mch receptor antagonist, antidiabetic agent imidazopyridine preparation mch receptor antagonist and other aspects.Computed Properties of 85386-20-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 4, 2021, Xu, Qing; Alt, Carsten; Li, Zhe; Nilar, Shahul; Rademacher, Peter Michael; Yee, Calvin Wesley published a patent.Category: pyrimidines The title of the patent was Prepartion of pyrimidines as ferroportin inhibitors. And the patent contained the following:

The invention is related to a method of inhibiting iron transport mediated by ferroportin in a subject, comprising administering to the subject an effective amount of a compound I [Z= N, CR5; R5 = H, halo, alkyl; R6 = independently at each occurrence halo, OH, (un)substituted alkoxy, alkyl, etc.; or two R6 groups, taken together with the atom to which each is attached, form an (un)substituted 5- or 6-membered monocyclic heterocyclyl fused with ring B, a C4-C7 cycloalkyl fused with ring B, a Ph fused with ring B, or a 5- to 6-membered monocyclic heteroaryl fused with ring B; n = 0-3; Y = (Y1)0-1; Y1-4 = independently CH, N, NH, O, S, SH, SR6, NR6, CR6; provided that 1 or 2 of Y1-4 can be N, NR6, NH, O, SH or SR6; R1, R2 = independently H, alkyl, haloalkyl, alkoxy, and OH; R1 and R2 taken together with the atom to which each is attached form ring A; wherein A = (un)substituted C5-C6 cycloalkyl, 5- or 6-membered heterocyclyl, Ph, and 5- or 6-membered heteroaryl; R3 = H , optionally deuterated C1-C3 alkyl, hydroxyalkyl, C1-C3 alkoxyalkyl, haloalkyl, cyclopropyl, phenyl; R4 = CH2CONH2 and derivatives, cycloalkyl, alkylsulfonylalkyl, etc.; or R3NR4 = (un)substituted4- to 12-membered heterocyclyl] and their pharmaceutical salts. The invention is laos relates to methods of administering them for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries and to pharmaceutical compositions containing compounds I. Preparation of compounds I and their pharmaceutical acceptable salts is also given. Thus, II was prepared in 6 steps from 2-chloro-4-methylpyridine and diethylcarbonate using N-tert-Butyl-2-[(2-chloro-5H,6H,7H-cyclopenta[d]pyrimidin-4-yl)amino]acetamide (preparation given). II was tested in an in vitro ferroportin internalization assay (pEC50 = 7.7). The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Category: pyrimidines

The Article related to pyrimdine cycloalkapyrimidine thienopyrimidine preparation ferroportin inhibitor, thienopyrimidine cyclopentapyrimidinyl amino acid amide preparation ferroportin inhibitor, hepcidin iron metabolism disorder cycloalkapyrimidine thienopyrimidine preparation, iron overload state thalassemia hemochromatosis treatment cycloalkapyridine thienopyrimidine preparation and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 1, 2017, Woodring, Jennifer L.; Bachovchin, Kelly A.; Brady, Kimberly G.; Gallerstein, Mitchell F.; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P. published an article.COA of Formula: C8H10BrN3O The title of the article was Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation. And the article contained the following:

Human African trypanosomiasis (HAT) is a deadly disease in need of new chemotherapeutics that can cross into the central nervous system. The authors previously reported the discovery of (NEU-617), a small mol. with activity against T. brucei bloodstream proliferation. Further optimization of NEU-617 to improve the physicochem. properties (LogP, LLE, [1], and MPO score) [2] have led us to twelve sub-micromolar compounds, most importantly the headgroup variants I and II, and the linker variant III. Although these 3 compounds had reduced potency compared to NEU-617, they all had improved LogP, LLE and MPO scores. Cross-screening these analogs against other protozoan parasites uncovered IV with potent activity towards T. brucei, T. cruzi and L. major, while four others compounds showed activity towards P. falciparum D6. This reinforces the effectiveness of lead repurposing for the discovery of new protozoan disease therapeutics. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).COA of Formula: C8H10BrN3O

The Article related to anilinoquinazoline trypanosome inhibitor antimalarial malaria trypanosomiasis trypanosomicide, human african trypanosomiasis, leishmania major, neglected tropical disease, plasmodium falciparum, target class repurposing, trypanosoma brucei, trypanosoma cruzi and other aspects.COA of Formula: C8H10BrN3O

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 30, 1981, Ishikawa, Fumiyoshi; Kosasayama, Akira; Yamaguchi, Hitoshi; Watanabe, Yoshifumi; Saegusa, Junji; Shibamura, Seiichi; Sakuma, Kyoko; Ashida, Shinichiro; Abiko, Yasushi published an article.SDS of cas: 42518-42-3 The title of the article was Cyclic guanidines. 14. Imidazo[1,2-a]thienopyrimidin-2-one derivatives as blood platelet aggregation inhibitors. And the article contained the following:

A series of novel 1,2,3,5-tetrahydroimidazo[1,2-a]thieno[2,3-d]-, and -[3,4-dpyrimidin-2-one derivatives were prepared and tested for the activity of inhibiting platelet aggregation in rats in vitro and ex vivo. They were prepared by the following reactions: NaBH4 reduction of 2,4-dichlorothienopyrimidines, followed by ethoxycarbonylmethylation and successive amination. Most of the compounds were found to be potent inhibitors of blood platelet aggregation. Structure-activity relationships indicated the essential contribution of the lactam structure and lipophilic substituents on the thiophene ring to the effective interaction of the compounds with a receptor site on the platelet. Among the compounds studied, 1,2,3,5,6,7,8,9-octahydro[1]benzothieno[1,2-d]imidazo[1,2-a]pyrimidin-2-one exhibited the most favorable activity. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).SDS of cas: 42518-42-3

The Article related to cyclic guanidine, imidazothienopyrimidinone preparation blood platelet, thienopyrimidinone imidazo, pyrimidinone imidazothieno, structure blood platelet imidazothienopyrimidinone, reduction ethoxycarbonylmethylation amination dichlorothienopyrimidine and other aspects.SDS of cas: 42518-42-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Kazemnejadi, Milad; Sardarian, Ali Reza; Esmaeilpour, Mohsen published an article in 2019, the title of the article was Introduction of two polyvinyl alcohol resins for efficient solid support Cu-catalyzed N-arylation of α-aminoacids with aryl halides in aqueous media.Category: pyrimidines And the article contains the following content:

In this article, two polyvinyl alc. (PVA)-based resins were prepared by crosslinking of epoxidized PVA-chains using of 4-(4-aminobenzyl)benzenamine as a crosslinker and polymerization of acrylated PVA chains in the another approach. The prepared PVA resins showed well hydrophilic and swelling properties in various organic solvents, which are used in solid-phase organic synthesis (SPOS). Swelling properties of these resins were examined in DMF, THF, water, ethanol, methanol, dichloromethane, and dioxane. Furthermore, the both resins were characterized by FTIR and 1H-NMR and their properties such as epoxy equivalent weight (EEW) of epoxidized PVA and d. of the resins were determined by anal. methods. Then, α-amino acids such as L-aspartic acid, L-leucine, L-alanine, L-serine, L-valine, L-threonine, and L-tyrosine were immobilized on both resins through esterification reaction between these α-amino acids with the present hydroxyl groups on PVA resins, to carry out their solid-phase N-arylation reaction in the presence of CuI as a catalyst in milder and greener conditions than free resin protocols. Hydrolysis of the corresponding N-arylated α-amino acids immobilized on the resins gave the N-arylated α-amino acids in high to excellent yields. © 2019 Wiley Periodicals, Inc.J. Appl. Polym. Sci. 2019, 136, 47597. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Category: pyrimidines

The Article related to amino acid arylation solid phase arylhalide green chem swelling, solid support recycling copper arylation polyvinyl alc resin hydrolysis, arylation reaction mechanism copper catalyst, aryl halide cross coupling reaction amino acid copper catalyst and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 2, 2004, Moriya, Minoru; Suzuki, Takao; Ishihara, Akane; Iwaasa, Hisashi; Kanatani, Akio published a patent.Recommanded Product: 5-Phenylpyrimidine-2-carboxylic acid The title of the patent was Preparation of pyrimidine derivatives having 2-aminoquinoline moiety as MCH receptor antagonists. And the patent contained the following:

Title compounds I [R1, R2 = alkyl, etc.; R3, R4, R6, R7 = H, alkyl, etc.; R5 = H, alkyl; R8 = halo, etc.; n = 0-4] were prepared For example, hydrogenation of nitro compound (R)-II followed by acylation with 5-phenylpyrimidine-2-carboxylic acid afforded compound (R)-III. In MCH (melanin concentrating hormone) binding assays, the IC50 value of compound (R)-III was 4.1 nM. Compounds I are claimed useful for the treatment of obesity, diabetes, etc. The experimental process involved the reaction of 5-Phenylpyrimidine-2-carboxylic acid(cas: 85386-20-5).Recommanded Product: 5-Phenylpyrimidine-2-carboxylic acid

The Article related to aminoquinoline preparation mch melanin concentrating hormone receptor antagonist, antiobesity aminoquinoline preparation mch melanin concentrating hormone receptor antagonist, antidiabetic agent aminoquinoline preparation mch receptor antagonist and other aspects.Recommanded Product: 5-Phenylpyrimidine-2-carboxylic acid

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Computed Properties of C6H6BrClN2On March 31, 1984, Sakamoto, Takao; Kondo, Yoshinori; Yamanaka, Hiroshi published an article in Synthesis. The article was 《Studies on pyrimidine derivatives; XXXV. Iodination of 2-aminopyrimidines, 4-aminopyrimidines, and 4-pyrimidinones with iodine chloride in situ》. The article mentions the following:

Iodination of pyrimidines I (R = H, Me, Me2CH, Ph; R1 = NH2; R2 = H; R3 = Me) with ICl generated in situ in AcOH gave 42-55% I (R, R1, R3 = same as above; R2 = I). Similarly, II (R, R2, R3 same as above) gave 51-72% II (R2 = I), which was chlorinated with POCl3 to give I (R, R3 = same, R1 = Cl, R2 = I), which was dechlorinated with p-MeC6H4SO2NHNH2 and Na2CO3 to give 77-87% I (R, R3 = same, R1 = H, R2 = I).5-Bromo-4-chloro-2,6-dimethylpyrimidine(cas: 69696-35-1Computed Properties of C6H6BrClN2) was used in this study.

5-Bromo-4-chloro-2,6-dimethylpyrimidine(cas: 69696-35-1) is a member of organic chlorides. Organic chlorides are compounds containing a carbon-chlorine bond, which are widely used in the oil field as a wax dissolver. They are generally not present in crude oils and are typically the result of additives, cleaning solutions or chemicals used for oil recovery.Computed Properties of C6H6BrClN2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Formula: C11H6ClF3N2On March 31, 2018, Hu, Wei-Kang; Li, Si-Hua; Ma, Xiu-Fang; Zhou, Shi-Xiong; Zhang, Qian-feng; Xu, Jing-Yu; Shi, Peng; Tong, Bi-Hai; Fung, Man-Keung; Fu, Lianshe published an article in Dyes and Pigments. The article was 《Blue-to-green electrophosphorescence from iridium(III) complexes with cyclometalated pyrimidine ligands》. The article mentions the following:

A series of 4, 6-disubstituted pyrimidine based iridium(III) complexes (1-5), has been synthesized with a simple method. Single X-ray structural analyses were conducted on 5 to reveal their coordination arrangement. These complexes exhibit almost single peak emission with the peak wavelength located in the range of 468-505 nm and quantum yields of over 75%. The relationship between photophys. properties and the substituent nature of the complexes was discussed by d. functional theory. Organic light-emitting diodes (OLEDs) were also fabricated using these complexes as dopants in 15 wt%. The green device based on 1 shows a maximum external quantum efficiency, current efficiency, and power efficiency of 9.7%, 46.5 cd A-1 and 29.0 lm W-1, resp., while the blue device based on 5 exhibits an external quantum efficiency of up to 14.5%, peak luminance efficiency of 28.0 cd A-1 and power efficiency of 19.5 lm W-1. Moreover, the Commission Internationale de L’Eclairage (CIE) coordinates of 5 are (0.15, 0.30) which is closer to blue emission than that of FIrpic. After reading the article, we found that the author used 4-Chloro-6-(4-(trifluoromethyl)phenyl)pyrimidine(cas: 659729-09-6Formula: C11H6ClF3N2)

4-Chloro-6-(4-(trifluoromethyl)phenyl)pyrimidine(cas: 659729-09-6) belongs to pyrimidine. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives, including the nucleotides cytosine, thymine and uracil, thiamine (vitamin B1) and alloxan. Formula: C11H6ClF3N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Dreher, Spencer D.; Ikemoto, Norihiro; Gresham, Venita; Liu, Jinchu; Dormer, Peter G.; Balsells, Jaume; Mathre, David; Novak, Thomas J.; Armstrong, Joseph D. published an article in Tetrahedron Letters. The title of the article was 《Highly selective synthesis of 2-substituted-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid derivatives using a novel protected dihydroxyfumarate》.Recommanded Product: 5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid The author mentioned the following in the article:

A high yielding (50-96%) route to 2-substituted-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid derivatives, e.g. I, has been developed using a rationally designed dihydroxyfumarate derivative The fully unprotected pyrimidinone heterocycle II was prepared in quant. yield upon treatment of I with HCl. In the experiment, the researchers used 5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid(cas: 62222-38-2Recommanded Product: 5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid)

5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid(cas: 62222-38-2) belongs to pyrimidine. Pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics. Recommanded Product: 5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia